Fluorine in PDB 8stg: Discovery and Clinical Validation of Rly-4008, the First Highly Selective FGFR2 Inhibitor with Activity Across FGFR2 Alterations and Resistance Mutations
Enzymatic activity of Discovery and Clinical Validation of Rly-4008, the First Highly Selective FGFR2 Inhibitor with Activity Across FGFR2 Alterations and Resistance Mutations
All present enzymatic activity of Discovery and Clinical Validation of Rly-4008, the First Highly Selective FGFR2 Inhibitor with Activity Across FGFR2 Alterations and Resistance Mutations:
2.7.10.1;
2.7.10.1;
Protein crystallography data
The structure of Discovery and Clinical Validation of Rly-4008, the First Highly Selective FGFR2 Inhibitor with Activity Across FGFR2 Alterations and Resistance Mutations, PDB code: 8stg
was solved by
R.Valverde,
L.Foster,
with X-Ray Crystallography technique. A brief refinement statistics is given in the table below:
| Resolution Low / High (Å) | 56.30 / 3.79 |
| Space group | P 21 21 21 |
| Cell size a, b, c (Å), α, β, γ (°) | 62.51, 91.34, 129.62, 90, 90, 90 |
| R / Rfree (%) | 26.9 / 31.9 |
Fluorine Binding Sites:
The binding sites of Fluorine atom in the Discovery and Clinical Validation of Rly-4008, the First Highly Selective FGFR2 Inhibitor with Activity Across FGFR2 Alterations and Resistance Mutations
(pdb code 8stg). This binding sites where shown within
5.0 Angstroms radius around Fluorine atom.
In total 2 binding sites of Fluorine where determined in the Discovery and Clinical Validation of Rly-4008, the First Highly Selective FGFR2 Inhibitor with Activity Across FGFR2 Alterations and Resistance Mutations, PDB code: 8stg:
Jump to Fluorine binding site number: 1; 2;
In total 2 binding sites of Fluorine where determined in the Discovery and Clinical Validation of Rly-4008, the First Highly Selective FGFR2 Inhibitor with Activity Across FGFR2 Alterations and Resistance Mutations, PDB code: 8stg:
Jump to Fluorine binding site number: 1; 2;
Fluorine binding site 1 out of 2 in 8stg
Go back to
Fluorine Binding Sites List in 8stg
Fluorine binding site 1 out
of 2 in the Discovery and Clinical Validation of Rly-4008, the First Highly Selective FGFR2 Inhibitor with Activity Across FGFR2 Alterations and Resistance Mutations
Mono view
Stereo pair view
Mono view
Stereo pair view
A full contact list of Fluorine with other atoms in the F binding
site number 1 of Discovery and Clinical Validation of Rly-4008, the First Highly Selective FGFR2 Inhibitor with Activity Across FGFR2 Alterations and Resistance Mutations within 5.0Å range:
|
Fluorine binding site 2 out of 2 in 8stg
Go back to
Fluorine Binding Sites List in 8stg
Fluorine binding site 2 out
of 2 in the Discovery and Clinical Validation of Rly-4008, the First Highly Selective FGFR2 Inhibitor with Activity Across FGFR2 Alterations and Resistance Mutations
Mono view
Stereo pair view
Mono view
Stereo pair view
A full contact list of Fluorine with other atoms in the F binding
site number 2 of Discovery and Clinical Validation of Rly-4008, the First Highly Selective FGFR2 Inhibitor with Activity Across FGFR2 Alterations and Resistance Mutations within 5.0Å range:
|
Reference:
V.Subbiah,
V.Sahai,
D.Maglic,
K.Bruderek,
B.B.Toure,
S.Zhao,
R.Valverde,
P.J.O'hearn,
D.T.Moustakas,
H.Schonherr,
N.Gerami-Moayed,
A.M.Taylor,
B.M.Hudson,
D.J.Houde,
D.Pal,
L.Foster,
H.Gunaydin,
P.Ayaz,
D.A.Sharon,
L.Goyal,
A.M.Schram,
S.Kamath,
C.A.Sherwin,
O.Schmidt-Kittler,
K.Y.Jen,
F.Ricard,
B.B.Wolf,
D.E.Shaw,
D.A.Bergstrom,
J.Watters.
Rly-4008, the First Highly Selective FGFR2 Inhibitor with Activity Across FGFR2 Alterations and Resistance Mutations Cancer Discov 2023.
ISSN: ESSN 2159-8290
DOI: 10.1158/2159-8290.CD-23-0475
Page generated: Thu Jul 27 14:49:08 2023
ISSN: ESSN 2159-8290
DOI: 10.1158/2159-8290.CD-23-0475
Last articles
Zn in 8WB0Zn in 8WAX
Zn in 8WAU
Zn in 8WAZ
Zn in 8WAY
Zn in 8WAV
Zn in 8WAW
Zn in 8WAT
Zn in 8W7M
Zn in 8WD3
